Merck KGaA, Darmstadt GermanyThis article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential role of a contract development and manufacturing organization (CDMO) with deep expertise in activated PEG chemistry is highlighted.
Authors: Raymond Behrendt, Silvia Kaden-Vagt, Lotfi Bouchekioua, Merck KGaA, Darmstadt, Germany
Organoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
BIMOVIS GmbHIn this interview Dr. Martin Stieler, founder and CEO of BIMOVIS, introduces his company and the importance of structural biology in biotech and pharmaceutical industries, and highlights how BIMOVIS helps unlock the full potential of biomolecular insights to advance drug development and strengthen R&D pipelines.
![Approvals of antibody-based therapies have accelerated sharply since 2000 with oncology dominating the landscape, newer modalities like ADCs and bispecifics gaining momentum [2]](https://european-biotechnology.com/wp-content/uploads/2025/10/Seite-71_EB325_Indivumed_Grafik1_RZ_X3-180x180.png)
Indivumed GmbHFifty years after the invention of hybridoma technology, biologics have become a cornerstone of oncology drug discovery and development. From the first monoclonal antibody approval in 1995 to today’s complex antibody formats and cell-based therapies, biologics are reshaping cancer drug discovery. Yet, despite remarkable progress, the urgent need for novel targets that can exploit recent technological developments remains high.
T3 PharmaceuticalsT3 Pharmaceuticals shows how a biotech can move from first experiments to a major international deal keeping pace – and roots – in the Basel Area. The team built, tested and scaled inside Switzerland Innovation Park Basel Area’s Main Campus. Flexible private labs, certified shared facilities and an on-site expert community cut friction at every step. The result: faster iteration, smarter use of capital and a clear path from seed to global relevance — all inside Europe’s densest life sciences cluster.
Celonic GroupThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.
Wien-Tourismus/Christian-StemperThis year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.
Rezon BioThe global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.
Watch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age categories in nonhuman primate research.
Download the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies across multiple European sites and jurisdictions.